Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | XDH | P47989 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.53 |
| ▸ | RELA | Q04206 | 1/20 | 0.53 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA7 | P43166 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.50 |
| ▸ | ESR1 | P03372 | 2/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL282481 | 0.87 | KDM4E (0.63) | KDM4EXDHLMNAPOLBGAA | |
| SCHEMBL282150 | 0.87 | KDM4E (0.63) | KDM4EXDHLMNAPOLBGAA | |
| Water SCHEMBL7957219 | 0.85 | KDM4E (0.61) | KDM4EXDHLMNAPOLBGAA | |
| SCHEMBL15796792 | 0.84 | CA12 (0.47) | KDM4EXDHLMNAPOLBGAA | |
| SCHEMBL8379866 | 0.82 | CA12 (0.46) | KDM4EXDHLMNAPOLBGAA | |
| SCHEMBL8335189 | 0.82 | NOTUM (0.46) | KDM4EXDHLMNAPOLBGAA | |
| SCHEMBL1420175 | 0.81 | LMNA (0.74) | KDM4EXDHLMNAPOLBGAA | |
| SCHEMBL8539124 | 0.81 | XDH (0.74) | KDM4EXDHLMNAPOLBGAA | |
| SCHEMBL15794881 | 0.81 | CA12 (0.52) | KDM4EXDHLMNAPOLBGAA | |
| SCHEMBL8336289 | 0.81 | CA1 (0.52) | KDM4EXDHLMNAPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220315565-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | FORMA THERAPEUTICS, INC. | 2022-10-06 | — | — | US | disclosed |
| US-11299484-B2 | Inhibiting fatty acid synthase (FASN) | FORMA THERAPEUTICS, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| CN-113329748-A | Inhibition of Fatty Acid Synthase (FASN) | 福马治疗股份有限公司 | 2021-08-31 | — | — | CN | disclosed |
| US-20210024508-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | FORMA THERAPEUTICS, INC. | 2021-01-28 | — | — | US | disclosed |
| US-20210024508-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | FORMA THERAPEUTICS, INC. | 2021-01-28 | — | — | US | disclosed |
| US-10875848-B2 | Inhibiting fatty acid synthase (FASN) | FORMA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200115368-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | FORMA THERAPEUTICS, INC. | 2020-04-16 | — | — | US | disclosed |
| EP-3636637-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | Forma Therapeutics, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-3636637-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | Forma Therapeutics, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-0207454-B1 | ISOXAZOLE AND FURAN DERIVATIVES, THEIR PREPARATION AND USE AS ANTIVIRAL AGENTS | STERLING WINTHROP INC. (US) | 1992-09-09 | — | — | EP | disclosed |
| US-5002960-A | Viricides for combating picornaviruses | STERLING DRUG, INC. (US) | 1991-03-26 | — | — | US | disclosed |
| US-4939267-A | Viricides | STERLING DRUG INC. (US) | 1990-07-03 | — | — | US | disclosed |
| US-4843087-A | OXAZOLINYL COMPOUNDS; RHINOVIRUSES AND PICORNAVIRUSES | STERLING DRUG INC. (US) | 1989-06-27 | — | — | US | disclosed |
| EP-0207454-A2 | Isoxazole and furan derivatives, their preparation and use as antiviral agents | STERLING WINTHROP INC. (US) | 1987-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10875848-B2 | Inhibiting fatty acid synthase (FASN) | FASN, SCD, FADS1 | KDM4E 3899/4885XDH 455/4885LMNA 1010/4885 |
| US-20210024508-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | FASN, SCD, FADS1 | KDM4E 3899/4885XDH 455/4885LMNA 1010/4885 |
| US-20200115368-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | FASN, SCD, FADS1 | KDM4E 3899/4885XDH 455/4885LMNA 1010/4885 |
| US-20220315565-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | FASN, SCD, FADS1 | KDM4E 3899/4885XDH 455/4885LMNA 1010/4885 |
| US-11299484-B2 | Inhibiting fatty acid synthase (FASN) | FASN, SCD, FADS1 | KDM4E 3899/4885XDH 455/4885LMNA 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.